Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ambulatory therapy with amphotericin B].

C Berger1, A Gratwohl, A Tichelli

  • 1Departement Innere Medizin, Kantonsspital Basel.

Schweizerische Medizinische Wochenschrift
|April 23, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone marrow transplantation·2016
Same author

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

Leukemia & lymphoma·2016

Outpatient treatment with amphotericin B (AmB) for systemic fungal infections is feasible and cost-effective. This approach minimizes drug toxicity risks and hospital stays, offering an acceptable alternative to inpatient care.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Context:

  • Systemic fungal infections require prolonged amphotericin B (AmB) therapy, typically inpatient due to toxicity concerns.
  • Traditional AmB treatment necessitates lengthy hospitalizations, increasing healthcare costs and patient burden.
  • Managing AmB toxicity, particularly renal impairment, is crucial for treatment continuation.

Purpose:

  • To evaluate the feasibility and safety of outpatient amphotericin B (AmB) therapy for systemic fungal infections.
  • To assess the side effect profile and renal function impact during ambulatory AmB treatment.
  • To determine the potential for cost reduction and patient benefit through outpatient AmB administration.

Summary:

  • A study treated 14 outpatients with 164 amphotericin B (AmB) infusions between 1983 and 1987.

Related Experiment Videos

  • Side effects were generally mild and manageable, with only one patient experiencing dose reduction due to renal impairment.
  • Outpatient AmB therapy proved feasible in an experienced unit, demonstrating potential for significant cost savings.

    • Impact:

    • Outpatient amphotericin B (AmB) therapy is a viable and cost-effective alternative to inpatient treatment.
    • This approach can reduce treatment costs and shorten hospital stays, benefiting patients, especially those with malignant diseases.
    • Successful ambulatory AmB administration highlights the potential for decentralized, patient-centered care in managing systemic fungal infections.